Argument and Contention over the Use of Low-dose Irradiation toCOVID-19 Pneumonia: A Comprehensive Review

Abstract

Background: The concept of Low Dose Radiation Therapy (LDRT) as a viable treatment for COVID-19 pneumonia, caused by the highly contagious single-stranded RNA virus of the Coronaviridae family, is investigated through a review of current clinical trials. LDRT has anti-inflammatory effects on pneumonia inflammation. This study examines the efficacy, toxicity and finding output of delivering LDRT to severe pneumonia patients.

Methods: This review was compiled using Google Scholar, PubMed, Scopus, Embase, and CINAHL with the following search terms: LDRT for COVID-19 Pneumonia patients, Total lung irradiation for COVID patients, and SARS-CoV-2 from 2019 to 2022. Articles without data, duplicates, or irrelevant to the review were excluded. The focus of this paper is to review the past use of low-dose radiation in treating several types of pneumonia and the current arguments for the benefit of low-dose radiation in the treatment of COVID-19.

Results: After selecting relevant reports, this study selected 8 clinical trials and based on them conducted this paper and analyzed its feasibility.  According to an analysis, the treatment increase clinical recovery and outcome shows 80% recovery of anti-inflammatory response from lung inflammation. It reduces oxygen supplementation requirements by more than 60% within 48 hours of LDRT treatment.

Conclusions: Low-dose radiation therapy (LDRT) has been effective against pneumonia of diverse etiology, and cost-effective treatment for elderly dying patients with COVID-19. In this study all the case, we find a highly effective approach using LDRT. In addition, greater clarity can be derived prior to using LDRT against Covid-19 Pneumonia patient if large scale preclinical studies and clinical trials are conducted.